180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent…
<!-- Name:DistributionId Value:8805071 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4500 -->…
Browsing Tag
180 Life Sciences Corp.
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment…
<!-- Name:DistributionId Value:8755029 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4500 -->…
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory…
PALO ALTO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory consultants from the US and the UK, met with the UK…
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s…
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences Corp. An embedded link has been added to the 5th…
180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory…
PALO ALTO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs…
180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held…
PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs…
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful…
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs…
180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021…
PALO ALTO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs…
180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly…
MENLO PARK, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs…